Apatinib mesylate tablets combined with docetaxel and nedaplatin in the treatment of advanced ovarian cancer by observational clinical study of postoperative patients

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-17011968

Enrollment

Unknown

Registered

2017-07-13

Start date

2017-07-12

Completion date

Unknown

Last updated

2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

observation group:Apatinib + docetaxel plus nedaplatin

control group: docetaxel plus nedaplatin

Eligibility

Sex/Gender

Female

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. aged more than 18 years old; 2. patients with advanced ovarian cancer treated by cytoreductive surgery; 3. ECOG score: 0-2 points; 4. more than the expected survival time in March; 5. the main organs function properly, that is, the following standards: (1) routine blood test standards should be consistent (within 14 days without blood transfusion and blood products, not using G-CSF and other hematopoietic stimulating factors to correct): HB=90 g/L; ANC= 1.5 * 10^9/L; PLT = 80 * 10^9/L; (2) biochemical examination should meet the following standards: TBIL 45 ml/min (Cockcroft-Gault formula); 6. Participants volunteered to join the study and signed informed consent, good compliance and follow up.

Exclusion criteria

Exclusion criteria: 1. with high blood pressure and the antihypertensive drug treatment can not be reduced to the normal range (>140 systolic blood pressure mmHg, diastolic blood pressure >90 mmHg) with I at or above the level of myocardial ischemia or myocardial infarction, arrhythmia (including QT interval = 440 MS) and II heart function insufficiency; 2. there are obvious factors affecting the absorption of oral drugs, such as inability to swallow, chronic diarrhea and intestinal obstruction; 3. abnormal coagulation function (INR > 1.5 or prothrombin time (PT) > ULN+4 seconds or APTT >1.5 ULN), with bleeding tendency or undergoing thrombolysis or anticoagulant therapy; 4. with central nervous system metastasis; 5. have a history of psychotropic substance abuse and unable to abstain from or have mental disorders; 6. clinically difficult to control infection or HIV infection; 7. The researchers judged other cases that might affect clinical studies and the outcome of the study.

Design outcomes

Primary

Measure	Time frame
TTP;	—

Secondary

Measure	Time frame
ORR;DFS;Quality of life score;	—

Countries

China

Contacts

Public ContactGuoqing Wang

Tumor Hospital of Shaanxi province

15109224579@163.com+86 15109224579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026